Search

Displaying results 3951 - 3960 of 7503 in total
  1. Drug

    Atigliflozin

    go.drugbank.com/drugs/DB21394
    Investigational

    Atigliflozin is under investigation in clinical trial NCT00361738 (Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment).

  2. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.

  3. Drug

    Fluorodopa (18F)

    go.drugbank.com/drugs/DB13848
    ApprovedInvestigational

    [L12849] Fluorodopa F 18 PET is used adjunctly with other diagnostic investigations and serves primarily to visualize dopaminergic nerve terminals in the striatum.[L12849]

  4. Drug

    VPM1002

    go.drugbank.com/drugs/DB15801
    Investigational

    The bacille Calmette-Guérin (BCG) vaccine protects against severe extrapulmonary forms of tuberculosis (TB) but does not adequately protect against pulmonary TB -- the most prevalent form of TB. … By reducing urease C, phagosome acidification can occur, promoting phagolysosome fusion while also providing the optimal low pH for listeriolysin O stability.

  5. Drug

    Melarsomine

    go.drugbank.com/drugs/DB11528
    ExperimentalVet approved

    Melarsomine is a trypanocidal agent marketed by Merial under the trade name Immiticide. … It is the only FDA-approved treatment for adult heartworm infection in dogs, however, is is not approved for use in dogs with late-stage infection.

  6. Drug

    AAV1-FS344

    go.drugbank.com/drugs/DB17855
    Investigational

    AAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor.

  7. Drug

    Becotatug

    go.drugbank.com/drugs/DB19069
    Investigational

    Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations). … Becotatug is under investigation in clinical trial NCT06380348 (JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung

  8. Drug

    MK-0354

    go.drugbank.com/drugs/DB05939
    Investigational

    MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. … It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.

  9. Drug

    Pegademase

    go.drugbank.com/drugs/DB00061
    ApprovedWithdrawn

    Bovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.

  10. Drug

    SNS-314

    go.drugbank.com/drugs/DB06134
    Investigational

    Proliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of endoreduplication and eventually cell death. … SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours.